Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Invivyd ( (IVVD) ) just unveiled an announcement.
On June 26, 2025, Invivyd, Inc. announced positive results from their Phase 1/2 clinical trial for VYD2311, a next-generation monoclonal antibody aimed at preventing and treating COVID-19. The trial demonstrated a favorable safety profile and long-lasting serum concentrations, suggesting that VYD2311 could offer robust protection against COVID-19 over extended periods. The company plans to discuss approval pathways with the FDA in early Q3 2025, aiming to provide scalable and accessible solutions for COVID-19 prevention and treatment, particularly for immunocompromised individuals.
The most recent analyst rating on (IVVD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. operates in the biotechnology industry, focusing on the development of monoclonal antibodies for the prevention and treatment of infectious diseases, particularly COVID-19. Their primary product offerings include next-generation monoclonal antibodies, such as VYD2311, which are designed to provide non-vaccine mediated protection against COVID-19, especially for vulnerable populations.
Average Trading Volume: 1,856,280
Technical Sentiment Signal: Sell
Current Market Cap: $84.49M
See more data about IVVD stock on TipRanks’ Stock Analysis page.